[Chamber Angle Assessment in Clinical Practice - A Comparison between Optical Coherence Tomography and Gonioscopy]. / Kammerwinkelbeurteilung im klinischen Alltag - ein Vergleich zwischen der optischen Kohärenztomografie und der Gonioskopie.

BACKGROUND: In glaucoma the structures of the anterior chamber are important for classification, therapy, progression and prognosis. In this context anterior segment optical coherence tomography (AS-OCT) gains more relevance. This study compares AS-OCT with gonioscopy in diagnostic performance of chamber angle (CA) assessment. PATIENTS AND METHODS: 104 consecutive subjects with glaucoma underwent AS-OCT imaging using the Visante OCT. RESULTS were compared to gonioscopic grading from patient history using the Shaffer system. In addition, anterior chamber depth (ACD) assessment using slitlamp examination was evaluated as a prognostic factor for chamber angle width (CAW) and verified by AS-OCT measurement. RESULTS: Average CAW was 29° (AS-OCT). 17 % of the CAs that were "wide" in gonioscopy (variance 5-55°), showed a "narrow" CA in AS-OCT. 35 % of the CAs that were "narrow" in gonioscopy (variance 0-39°) showed a "wide" CA in AS-OCT. ACD assessment using slitlamp examination is a good predictor for CAW. In this context the technique provides equal informative value as gonioscopy. In cases of "wide" ACDs it is even superior. The critical ACD for an increased risk of angle closure is 2.4 mm. Concerning the critical ACD (< 2.4 mm) the technique gave the possibility to estimate, whether the patients were in the crucial range or not. Average ACD was 2.7 mm (AS-OCT). A strong correlation (correlation coefficient 0.83) between ACD and CAW was observed. Variation of 1 mm in the ACD leads to a change of 18.9° in the CAW. All patients with angle closure glaucoma were below this threshold and 74 % of patients with critical ACD had "narrow" (AS-OCT) CAs. CONCLUSION: In the case of routine clinical practice with inexperienced residents or circumstances that make gonioscopy difficult or impossible, optical coherence tomography is an effective alternative to the gold standard and is to some extent even superior.

[Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins]. / Grundlegende In-vitro-Untersuchungen zur VEGF-Inhibition mit Aflibercept: Gemeinsamkeiten und Unterschiede zu anderen VEGF-bindenden therapeutischen Proteinen.

Patients suffering from various retinal diseases benefit from therapies directed against the vascular endothelial growth factor (VEGF). Aflibercept (Eylea) is another VEGF-binding protein available for intravitreal injection, in addition to the antibody bevacizumab (Avastin) and the F(ab) fragment ranibizumab (Lucentis). Aflibercept's distinct structure and broader binding specificity may have clinically relevant consequences, which is supported by basic in vitro studies and observations in animal eyes. All pathological processes involving neovascularisation are driven by the dominant action of VEGF, but other factors including placenta growth factor (PlGF), a mitogenic protein for retinal endothelial cells, potentially modulate its effects. Aflibercept is an inhibitor of both VEGF and PlGF and therefore may have superior therapeutic effects in some cases. However, whether or not aflibercept's broader binding specificity or different affinities for the different VEGF-binding proteins to VEGF result in substantially diverse therapeutic efficiencies has not yet been clarified. In vitro studies confirm that aflibercept efficiently prevents or normalises VEGF-stimulation of retinal cells and disturbance of their barrier function. These experiments also show that aflibercept is taken up by important retinal cell types and affects their normal function, i.e., migration of endothelial cells and phagocytosis of pigment epithelial cells. In accordance with a role of the Fc domains of aflibercept and bevacizumab, substantial amounts of both proteins are internalised, whereas only a small portion of ranibizumab enters the cells. Internalisation and storage by ocular cells, also observed in vivo after intravitreal injection into eyes of monkeys, may result in not yet recognised side effects during long-term treatment of patients with certain VEGF-binding proteins.

[Demodex folliculorum: diagnosis and therapy today]. / Demodex folliculorum: Diagnostik und Therapie im klinischen Alltag.

Demodex folliculorum is an ectoparasite found in eye lashes. A Demodex-associated blepharoconjunctivitis is common. Demodex are diagnosed via microscopy in a drop of oil after epilation of a few eye lashes. You can often watch the mites in movement under the microscope. Treatment includes lid hygiene and metronidazole gel 1-2 %. The treatment often improves the symptoms of the patient. Demodex folliculorum is often found in patients with persistent blepharoconjunctivitis. Every ophthalmologist should have a microscope to find the mites. Then you will be able to treat the patients in an early stage.

[Ophthalmopathology in everyday clinical routine]. / Ophthalmopathologie im klinischen Einsatz.

This article is intended to take up the cudgels on behalf of ophthalmopathology. To achieve this it is required to shed a light on ophthalmopathology in everyday clinical routine and to emphasise its relevance in today's world. Furthermore, it is intended to show how ophthalmopathology (unconsciously in part) has an impact on our actions. An ophthalmopathologist thinks differently, diagnoses differently and operates differently! Therefore ophthalmopathology should be a cornerstone not only in patient care but also in research and education.

[Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies]. / Therapie des diabetischen Makulaödems mit den VEGF-Inhibitoren Ranibizumab und Bevacizumab: Schlüsse aus grundlegenden In-vitro-Untersuchungen.

Diabetic macular oedema (DMO) which may occur at all stages of diabetic retinopathy (DR) is a severe vision-threatening complication. In most cases, laser treatment does not improve visual acuity. Therefore research in ophthalmology focuses on the improvement of the prognosis of DMO patients with a drug-based DMO therapy. Vascular endothelial growth factor (VEGF) is considered the most important therapeutic target because this growth factor also is the most potent permeability factor affecting the inner retinal barrier formed by endothelial cells (ECs). Compared to its angiogenic stimulation of proliferation and migration of ECs, effects of VEGF on permeability have not been studied in all details. In vitro investigations on the behaviour of primary or immortalised retinal endothelial cells confirmed the key role of VEGF in the regulation of the permeability of the inner retinal barrier. Despite the presence of a variety of other factors found to be elevated in DR, a VEGF-disrupted barrier can be completely restored with the VEGF-inhibiting ranibizumab (Lucentis®) and bevacizumab (Avastin®) when applied at clinically achievable concentrations. The antibody bevacizumab, but not the antibody fragment ranibizumab, accumulates in both retinal EC and pigment epithelial cells during prolonged treatment. This observation might be relevant because patients are often treated for several years and additional long-term side effects may be recognised in the future.

[Applications of optical coherence tomography in the anterior segment]. / Anwendungsmöglichkeiten der optischen Kohärenztomografie im vorderen Augenabschnitt.

Optical coherence tomography provides high-resolution images of the anterior segment (AS-OCT). When used as a measuring tool, corneal thickness, anterior and posterior chamber depths, anterior chamber diameter and chamber angle configuration are defined reproducibly. In terms of an optical biopsy by cellular imaging, tissue infiltration, deformation and deposits can be analysed microstructurally. A comparison of pre- and post-operative, as well as long-term follow-up of pathological findings are possible. Examination with AS-OCT is a no-contact procedure, and is well tolerated by the patient. The following instruments were used: Visante-OCT and Cirrus HD-OCT (Carl Zeiss Meditec GmbH, Germany) and SS100 CASIA (Tomey Europe, Erlangen).

[Adoption of OSCE Examination Procedures in Ophthalmology]. / Etablierung der OSCE-Prüfungsmethode in der Ophthalmologie.

BACKGROUND: The department of ophthalmology at the medical faculty of the University of Ulm provides additionally for interested students in clinical semesters an optional activity. In small groups the students deepen their theoretical knowledge and learn more about ophthalmological diagnostic standard procedures. The "objective structured clinical examination" (OSCE) is known as a useful tool in the assessment of clinical skills. The OSCE is a well-established and valid examination method, but also time-consuming and costly. In form of a trial the OSCE was launched during the optional activity "Look into my eyes, baby"; in the summer semester 2009. METHODS: By means of four examination areas established diagnostic methods in ophthalmology were tested. During the tests two simulation patients as well as two phantom heads for ophthalmological examinations were assessed. The preparation of the examination materials occurred in close collaboration with the department of ophthalmology and the division exam development of our university. In the assessment of the examinations a high value was set on good communication skills between students and simulation patients as well as on the professional handling of the student tasks. After the examinations the acceptance of the test methods was evaluated using a focused group interview between the students of the optional activity and the participating examiners. RESULTS: We performed two OSCEs involving three students each in the last two semesters. The OSCE was to a great extent time- and resource-consuming, due to the intensive pre- and post-reviewing and the time students needed to pass the various examination areas. Students and examiners as well confirmed the validity of the assessment and acknowledged a positive effect on the students learning behaviour. CONCLUSIONS: The teaching staff members are willing to accept the OSCE, especially when the assessment procedures are thoroughly planned and well structured. The acceptance of the students can be achieved by providing valid assessment and reviewed teaching conditions. The high input in personnel and instrumental resources for the assessment and the student's individual supervision should be critically discussed in the light of the efficacy of the additional ongoing hospital and outpatient services and the personnel-relevant education budget assigned to the department of ophthalmology of a university.

[Photodynamic therapy with verteporfin in occult choroidal neovascularization in age-related macular degeneration]. / Photodynamische Therapie mit Verteporfin bei okkulter chorioidaler Neovaskularisation im Rahmen der altersbezogenen Makuladegeneration.

OBJECTIVE: We investigated retrospectively the clinical outcome of photodynamic therapy (PDT) with verteporfin (Visudyne) in patients with exudative age-related macular degeneration (ARMD) and subfoveal occult choroidal neovascularization (OCN). METHODS: 77 consecutive patients (90 eyes) with OCN were retrospectively analysed using a standardised protocol. It included best corrected visual acuity (BCVA) pre- and post-PDT, greatest linear dimension of OCN (GLD), ophthalmoscopic findings, optical coherence tomography (OCT), fundus photography and fluorescein angiography (FAG). The findings were descriptively analysed by Spearman rank correlation and cross-tabulation. RESULTS: Age ranged from 52 to 92 years (median: 79 years). 7 (8 %) of 90 PDT eyes gained > or = 2 lines, 67 (74 %) eyes stabilised with +/- 1 line. 17 eyes (18 %) showed a deterioration with loss of > or = 2 lines. BCVA of all cases was pre-PDT 0.33 (+/- 0.2), post-PDT 0.27 (+/- 0.2, p < 0.05), in the improvement group pre-PDT 0.4, post-PDT 0.7 in the stable cases pre-/post-PDT 0.3 and in the deterioration group pre-PDT 0.4 and post-PDT 0.2. GLD of all cases was pre-PDT 3.91 mm (minimum: 0.76 mm, maximum: 5.43 mm). From 86 eyes with OCT follow-up of at least 3 months 51 (60 %) had dry macula after last PDT and 35 (40 %) persistent macular edema (ME) in OCT. In 21 eyes (23 %) with leakage of fluorescein after last PDT, treatment was terminated. 10 eyes (47 %) had retinal angiomatous proliferation stage III, of these, 6 eyes presented with retinochoroidal anastomoses. 4 eyes (18 %) showed after PDT retinochoroidal anastomoses, 2 (10 %) vitreomacular traction in epiretinal membrane of the macula, 2 (10 %) had a tear of the retinal pigment epithelium, 1 (5 %) eye had a gain of GLD > 7200 microm, in 1 eye (5 %) BCVA was < 0.05 and in 1 eye (5 %) treatment was stopped at request of the patient. CONCLUSIONS: According to our study PDT might be helpful in the treatment of OCN in ARMD patients for stabilisation but not for improvement of BCVA. Results from large multicentre studies show that concerning BCVA ranibizumab (Lucentis) is superior to PDT in OCN. Further studies are required to investigate the outcome of combined therapy with PDT and VEGF inhibitors for reducing the number of treatments or the number of recurrences of choroidal neovascularisation.